6Reitberg DP, Marble DA,Schuhz,RW, et al. Pharmacokinet- ics of Cefoperazone (2.0 g) and Sulbactam ( 1.0 g) Coad- ministered to Subjects with Normal Renal Function, Patients with Decreased Renal Function, and Patients with End-Stage Renal Disease on Hemodialysis [ J ]. Antimicrobial Agents and Chemotherapy, 1988,32(4) :503-509.
7Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestsations, potential pathogenic mechanisms,and the role of electroencephalographic monitoring[J]. Ann Phar- macother, 2008, 42(12) : 1843-1850.
8Grill MF,Maganti RK. Neurotoxic effects associated with an- tibiotic use : management considerations [ J ]. British Journal of Clinical Pharmacology,2011,72 ( 3 ) :381-393.
9Sugimoto M, Uchida I, Mashimo T, et al. Evidence for the involvement of GABA (A) receptor blockage in convulsions induced by cephalosporins [ J ]. Neuropharmacology, 2003,45 (3) :304-314.
10Manian FA, Stone WJ, Alford RH. Adverse antibiotic effects associated with renal insufficiency[ J]. Rev Infect Dis, 1990,9 (12) :236-249.
